{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.7","value":"20.2"},{"groupId":"OG001","spread":"14.2","value":"19.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with osteosarcoma and Ewing sarcoma, rhabdomyosarcoma, non rhabdomyosarcoma soft tissue sarcoma, and other sarcomas were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants with solid tumor other (STO) were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever came occurred first.","id":"OG001","title":"STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the CSP for whom any post-dose data were available who did not violate or deviate from the CSP in ways that would significantly affect the PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12","title":"Dose-Expansion Phase: Cmax/D of Durvalumab","type":"SECONDARY","unitOfMeasure":"(mcg/mL)/(mg/kg)"}